Fagron NV (FAGR) - Total Assets
Based on the latest financial reports, Fagron NV (FAGR) holds total assets worth €1.53 Billion EUR (≈ $1.78 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fagron NV - Total Assets Trend (2004–2025)
This chart illustrates how Fagron NV's total assets have evolved over time, based on quarterly financial data. Also see market value of Fagron NV for the company's overall valuation and market capitalisation.
Fagron NV - Asset Composition Analysis
Current Asset Composition (December 2025)
Fagron NV's total assets of €1.53 Billion consist of 37.2% current assets and 62.8% non-current assets. Review FAGR current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 14.9% |
| Accounts Receivable | €95.24 Million | 7.7% |
| Inventory | €158.91 Million | 12.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €99.67 Million | 8.0% |
| Goodwill | €471.10 Million | 37.9% |
Asset Composition Trend (2004–2025)
This chart illustrates how Fagron NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Fagron NV stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fagron NV's current assets represent 37.2% of total assets in 2025, a decrease from 44.2% in 2004.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2025, up from 1.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 21.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 37.9% of total assets.
Fagron NV Competitors by Total Assets
Key competitors of Fagron NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Fagron NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.77 | 1.76 | 1.43 |
| Quick Ratio | 1.02 | 1.06 | 0.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €216.19 Million | €161.21 Million | €75.36 Million |
Fagron NV - Advanced Valuation Insights
This section examines the relationship between Fagron NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.64 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 14.7% |
| Total Assets | €1.24 Billion |
| Market Capitalization | $1.55 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Fagron NV's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Fagron NV's assets grew by 14.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fagron NV (2004–2025)
The table below shows the annual total assets of Fagron NV from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.24 Billion ≈ $1.45 Billion |
+14.73% |
| 2024-12-31 | €1.08 Billion ≈ $1.27 Billion |
+7.60% |
| 2023-12-31 | €1.01 Billion ≈ $1.18 Billion |
+3.70% |
| 2022-12-31 | €971.01 Million ≈ $1.14 Billion |
+21.31% |
| 2021-12-31 | €800.42 Million ≈ $935.78 Million |
+6.32% |
| 2020-12-31 | €752.83 Million ≈ $880.13 Million |
-6.04% |
| 2019-12-31 | €801.24 Million ≈ $936.73 Million |
+17.35% |
| 2018-12-31 | €682.77 Million ≈ $798.23 Million |
+14.94% |
| 2017-12-31 | €594.05 Million ≈ $694.50 Million |
-31.57% |
| 2016-12-31 | €868.05 Million ≈ $1.01 Billion |
+25.92% |
| 2015-12-31 | €689.38 Million ≈ $805.96 Million |
-29.20% |
| 2014-12-31 | €973.75 Million ≈ $1.14 Billion |
+21.01% |
| 2013-12-31 | €804.69 Million ≈ $940.77 Million |
+7.45% |
| 2012-12-31 | €748.89 Million ≈ $875.54 Million |
+10.09% |
| 2011-12-31 | €680.23 Million ≈ $795.26 Million |
+18.59% |
| 2010-12-31 | €573.59 Million ≈ $670.59 Million |
+21.48% |
| 2009-12-31 | €472.16 Million ≈ $552.00 Million |
+13.03% |
| 2008-12-31 | €417.73 Million ≈ $488.37 Million |
+20.22% |
| 2007-12-31 | €347.47 Million ≈ $406.23 Million |
+21.72% |
| 2006-12-31 | €285.46 Million ≈ $333.73 Million |
+4.93% |
| 2005-12-31 | €272.04 Million ≈ $318.04 Million |
-0.42% |
| 2004-12-31 | €273.19 Million ≈ $319.39 Million |
-- |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more